GridAI Technologies (GRDX)
Market Price (3/30/2026): $2.15 | Market Cap: $3.6 MilSector: Health Care | Industry: Biotechnology
GridAI Technologies (GRDX)
Market Price (3/30/2026): $2.15Market Cap: $3.6 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -40% | Weak multi-year price returns2Y Excs Rtn is -105%, 3Y Excs Rtn is -161% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Megatrend and thematic driversMegatrends include Artificial Intelligence, and Smart Grids & Grid Modernization. Themes include AI Software Platforms, Edge AI, Show more. | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -3.6 Mil | |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -436% | ||
| High stock price volatilityVol 12M is 146% | ||
| Key risksGRDX key risks include [1] internal governance friction following recent director resignations, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -40% |
| Megatrend and thematic driversMegatrends include Artificial Intelligence, and Smart Grids & Grid Modernization. Themes include AI Software Platforms, Edge AI, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -105%, 3Y Excs Rtn is -161% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -3.6 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -436% |
| High stock price volatilityVol 12M is 146% |
| Key risksGRDX key risks include [1] internal governance friction following recent director resignations, Show more. |
Qualitative Assessment
AI Analysis | Feedback
GridAI Technologies (GRDX) stock has lost about 25% since 11/30/2025 because of the following key factors:
1. Persistent Unprofitability and Lack of Revenue from Core Operations: GridAI Technologies reported a net loss of -$15.65 million for the trailing 12 months ending September 30, 2025, and its fiscal year revenue was $0.00 USD. The company continues to operate at a loss, which significantly impacts investor confidence and valuation, especially as it simultaneously invests in new ventures.
2. Market Skepticism on AI Sector Valuations and Unproven Business Models: While the broader market experienced an AI investment boom, there are increasing concerns about an "AI investment bubble" and elevated valuations for AI-related companies, particularly those without demonstrated profitability. Investors are seeking tangible proof of productivity improvements and profitability from AI investments in 2026, and a failure to meet these expectations could deflate the market. GridAI's stock decline suggests investors are scrutinizing its AI-driven energy orchestration platform as speculative, given the absence of significant revenue generation from these initiatives despite positive announcements about partnerships.
Show more
1. Persistent Unprofitability and Lack of Revenue from Core Operations: GridAI Technologies reported a net loss of -$15.65 million for the trailing 12 months ending September 30, 2025, and its fiscal year revenue was $0.00 USD. The company continues to operate at a loss, which significantly impacts investor confidence and valuation, especially as it simultaneously invests in new ventures.
2. Market Skepticism on AI Sector Valuations and Unproven Business Models: While the broader market experienced an AI investment boom, there are increasing concerns about an "AI investment bubble" and elevated valuations for AI-related companies, particularly those without demonstrated profitability. Investors are seeking tangible proof of productivity improvements and profitability from AI investments in 2026, and a failure to meet these expectations could deflate the market. GridAI's stock decline suggests investors are scrutinizing its AI-driven energy orchestration platform as speculative, given the absence of significant revenue generation from these initiatives despite positive announcements about partnerships.
Show more
Stock Movement Drivers
Fundamental Drivers
The -26.8% change in GRDX stock from 11/30/2025 to 3/29/2026 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 11302025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.99 | 2.19 | -26.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 2 | 2 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| GRDX | -26.8% | |
| Market (SPY) | -5.3% | 19.0% |
| Sector (XLV) | -8.7% | 6.5% |
Fundamental Drivers
The -3.7% change in GRDX stock from 8/31/2025 to 3/29/2026 was primarily driven by a -3.9% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 8312025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.27 | 2.19 | -3.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 2 | 2 | -3.9% |
| Cumulative Contribution | 0.0% |
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| GRDX | -3.7% | |
| Market (SPY) | 0.6% | 11.6% |
| Sector (XLV) | 5.2% | -6.4% |
Fundamental Drivers
The 47.6% change in GRDX stock from 2/28/2025 to 3/29/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.48 | 2.19 | 47.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 2 | 2 | -8.2% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| GRDX | 47.6% | |
| Market (SPY) | 9.8% | 6.5% |
| Sector (XLV) | -2.1% | 1.3% |
Fundamental Drivers
The -99.0% change in GRDX stock from 2/28/2023 to 3/29/2026 was primarily driven by a -99.8% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282023 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 213.60 | 2.19 | -99.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 2 | -99.8% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| GRDX | -99.0% | |
| Market (SPY) | 69.4% | 2.2% |
| Sector (XLV) | 18.4% | 0.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| GRDX Return | -85% | -98% | -97% | -85% | 150% | -56% | -100% |
| Peers Return | 52% | -31% | 92% | 61% | 33% | -14% | 268% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| GRDX Win Rate | 17% | 8% | 8% | 42% | 42% | 0% | |
| Peers Win Rate | 65% | 33% | 72% | 70% | 55% | 33% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| GRDX Max Drawdown | -86% | -99% | -97% | -94% | -45% | -56% | |
| Peers Max Drawdown | -7% | -40% | -5% | -4% | -19% | -16% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MSFT, GOOGL, AMZN, NVDA, IBM.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
| Event | GRDX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -100.0% | -25.4% |
| % Gain to Breakeven | 2649318.6% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -70.9% | -33.9% |
| % Gain to Breakeven | 244.0% | 51.3% |
| Time to Breakeven | 312 days | 148 days |
| 2018 Correction | ||
| % Loss | -91.0% | -19.8% |
| % Gain to Breakeven | 1008.9% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to MSFT, GOOGL, AMZN, NVDA, IBM
In The Past
GridAI Technologies's stock fell -100.0% during the 2022 Inflation Shock from a high on 1/25/2021. A -100.0% loss requires a 2649318.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About GridAI Technologies (GRDX)
Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.
AI Analysis | Feedback
nullAI Analysis | Feedback
nullAI Analysis | Feedback
nullAI Analysis | Feedback
null
AI Analysis | Feedback
nullAI Analysis | Feedback
The key risks for GridAI Technologies (GRDX) are primarily associated with the inherent challenges of its diversified business model, encompassing both late clinical-stage biopharmaceutical development and a new venture into AI-driven energy orchestration software.
- Clinical Development and Regulatory Approval Risk: As a late clinical-stage biopharmaceutical company, GridAI Technologies faces substantial risks associated with the development of its pipeline candidates, including latiglutenase, capeserod, adrulipase, and niclosamide. The high failure rate of clinical trials means that these candidates may not prove to be safe or effective, or may experience significant delays or unexpected adverse events. Failure to successfully complete clinical trials or obtain necessary regulatory approvals from health authorities would prevent the company from bringing its therapies to market, significantly impacting its financial viability and future prospects.
- Market Adoption and Competitive Risk in AI/Energy Sector: GridAI Technologies' recent diversification into AI-native energy-orchestration software introduces risks related to market acceptance and intense competition. The company's platform aims to coordinate grid power and manage energy systems for hyperscale AI campuses and distributed energy, a rapidly evolving and competitive market. There is a risk that the company's technology may not achieve sufficient market adoption, or that existing or new competitors could offer superior or more cost-effective solutions, limiting GridAI Technologies' ability to generate substantial revenue from this new segment.
- Funding and Commercialization Risk: Both the biopharmaceutical development and the scaling of a new AI/energy software platform are capital-intensive endeavors. GridAI Technologies currently operates with a relatively small market capitalization and negative EBITDA, indicating a reliance on external financing to fund ongoing operations, clinical trials, and technological development. The inability to secure adequate funding in the future, or challenges in successfully commercializing its products and software even if approved or adopted, could severely constrain the company's growth and operational continuity.
AI Analysis | Feedback
nullAI Analysis | Feedback
nullAI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for GridAI Technologies (GRDX) over the next 2-3 years:
- Addressing Hyperscale AI Data Center Energy Demand: GridAI Technologies is positioned to capitalize on the rapidly increasing electricity consumption and complex energy management needs of hyperscale AI data centers. The company develops grid and power-management software aimed at these campuses, providing an AI-driven energy orchestration platform that optimizes energy usage, manages grid connections, and coordinates distributed energy resources. With AI data centers projected to drive significant incremental power demand in the coming years, the demand for GridAI's solutions in this sector is a key revenue driver.
- Expansion and Adoption of the AI-Driven Energy Orchestration Platform: The company's core technology, an AI-driven software and control platform, enables utilities, retail energy providers, and large power users to dynamically manage load and distributed energy resources, including battery energy storage systems, on-site generation, and renewables. As the energy landscape becomes more complex due to electrification and distributed energy resources, the increased adoption of this platform by a broader range of customers, seeking to improve efficiency, reduce costs, and participate in grid services markets, is expected to drive revenue growth.
- Continued Advancement of Biopharmaceutical Pipeline: Despite its expanded focus on AI and energy infrastructure, GridAI Technologies (formerly Entero Therapeutics, Inc.) continues to advance its late clinical-stage biopharmaceutical programs targeting gastrointestinal diseases. The company's pipeline includes candidates such as latiglutenase for celiac disease (Phase 2), capeserod for gastroparesis (Phase 1), adrulipase for exocrine pancreatic insufficiency (Phase 2), and niclosamide for ulcerative proctitis/proctosigmoiditis and immune checkpoint inhibitor-associated colitis/diarrhea (Phase 2). Successful progression through clinical trials and potential commercialization of these therapeutic candidates represent significant future revenue opportunities.
AI Analysis | Feedback
nullTrade Ideas
Select ideas related to GRDX.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02202026 | MSFT | Microsoft | Insider | Insider Buys | Low D/EStrong Insider BuyingCompanies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap | -1.1% | -1.1% | -3.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 217.84 |
| Mkt Cap | 2,393.0 |
| Rev LTM | 260,696 |
| Op Inc LTM | 104,507 |
| FCF LTM | 42,360 |
| FCF 3Y Avg | 42,890 |
| CFO LTM | 121,116 |
| CFO 3Y Avg | 89,206 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 15.1% |
| Rev Chg 3Y Avg | 12.5% |
| Rev Chg Q | 16.7% |
| QoQ Delta Rev Chg LTM | 4.0% |
| Op Mgn LTM | 32.0% |
| Op Mgn 3Y Avg | 30.5% |
| QoQ Delta Op Mgn LTM | 0.4% |
| CFO/Rev LTM | 40.9% |
| CFO/Rev 3Y Avg | 36.6% |
| FCF/Rev LTM | 18.2% |
| FCF/Rev 3Y Avg | 20.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 2,393.0 |
| P/S | 8.2 |
| P/EBIT | 19.4 |
| P/E | 23.6 |
| P/CFO | 16.6 |
| Total Yield | 4.0% |
| Dividend Yield | 0.2% |
| FCF Yield 3Y Avg | 2.2% |
| D/E | 0.0 |
| Net D/E | -0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -5.3% |
| 3M Rtn | -18.2% |
| 6M Rtn | -12.6% |
| 12M Rtn | 27.7% |
| 3Y Rtn | 99.1% |
| 1M Excs Rtn | -1.6% |
| 3M Excs Rtn | -6.0% |
| 6M Excs Rtn | -8.3% |
| 12M Excs Rtn | 1.1% |
| 3Y Excs Rtn | 44.8% |
Price Behavior
Price Behavior
| Market Price | $2.19 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 10/11/2016 | |
| Distance from 52W High | -61.1% | |
| 50 Days | 200 Days | |
| DMA Price | $2.69 | $2.86 |
| DMA Trend | up | down |
| Distance from DMA | -18.6% | -23.4% |
| 3M | 1YR | |
| Volatility | 124.6% | 146.2% |
| Downside Capture | 0.50 | -0.29 |
| Upside Capture | -85.31 | 10.62 |
| Correlation (SPY) | 12.5% | 5.9% |
GRDX Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.32 | 1.31 | 2.74 | 1.00 | 0.44 | 0.17 |
| Up Beta | -1.75 | -0.12 | -0.69 | -0.02 | 0.36 | -0.18 |
| Down Beta | 5.83 | 6.19 | 6.77 | 4.81 | 1.41 | 0.73 |
| Up Capture | -235% | -176% | 102% | -16% | 23% | -6% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 8 | 17 | 26 | 59 | 119 | 324 |
| Down Capture | 151% | 127% | 245% | -34% | -28% | 100% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 11 | 22 | 33 | 63 | 130 | 412 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GRDX | |
|---|---|---|---|---|
| GRDX | 26.2% | 146.0% | 0.79 | - |
| Sector ETF (XLV) | 0.3% | 17.6% | -0.13 | -1.2% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | 5.9% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | -8.4% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | -0.1% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | -2.2% |
| Bitcoin (BTCUSD) | -23.7% | 44.2% | -0.49 | 15.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GRDX | |
|---|---|---|---|---|
| GRDX | -89.6% | 138.4% | -0.98 | - |
| Sector ETF (XLV) | 6.0% | 14.5% | 0.23 | 2.1% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | 6.4% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | -3.9% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | -1.2% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | 3.6% |
| Bitcoin (BTCUSD) | 4.0% | 56.6% | 0.29 | 3.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GRDX | |
|---|---|---|---|---|
| GRDX | -71.6% | 118.2% | -0.57 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.48 | 6.5% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 9.7% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | -2.4% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | 2.8% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 6.2% |
| Bitcoin (BTCUSD) | 66.4% | 66.8% | 1.06 | 3.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/19/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 04/01/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 10/21/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/29/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 03/20/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| 03/31/2022 | 05/23/2022 | 10-Q |
| 12/31/2021 | 03/31/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Romano, Sarah | Chief Financial Officer | Direct | Sell | 1082025 | 0.64 | 727 | 465 | 11,064 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.